Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Queralt Serra-Camprubí,Helena Verdaguer,Winona Oliveros, Núria Lupión-Garcia,Alba Llop-Guevara,Cristina Molina,Maria Vila-Casadesús,Anthony Turpin,Cindy Neuzillet,Joan Frigola,Jessica Querol, Mariana Yáñez-Bartolomé,Florian Castet,Carles Fabregat-Franco,Carmen Escudero-Iriarte,Marta Escorihuela,Enrique J Arenas,Cristina Bernadó-Morales,Noemí Haro, Francis J Giles,Óscar J Pozo,Josep M Miquel,Paolo G Nuciforo,Ana Vivancos,Marta Melé,Violeta Serra,Joaquín Arribas,Josep Tabernero,Sandra Peiró, Teresa Macarulla,Tian V Tian

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

Cited 1|Views55

No score

Abstract

Our results suggest that patients with advanced CCA with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1, are likely to benefit from PARPi therapy. This collection of CCA_PDXs provides new opportunities for evaluating drug response and prioritizing clinical trials.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined